Clinical Trials Browser

Completed × Observational × Brentuximab Vedotin × Clear all

NCT04213209 2024-09-27

Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma"

95 enrolled 30 charts

Lymphoma, T-Cell, Peripheral

NCT02139592 2020-07-13

Brentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillance (All-case Surveillance) "Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma"

292 enrolled 39 charts

Recurrence, Lymphoma, Large-Cell, Anaplastic